1683.45 6.60 (0.39%)
1.8M NSE+BSE Volume
NSE 13 Mar, 2025 3:31 PM (IST)
Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
---|---|---|---|---|---|---|---|---|---|---|---|
14 Mar 2025 | Sun Pharmaceutical | Consensus Share Price Target | 1683.45 | 2056.16 | - | 22.14 | buy | ||||
11 Mar 2025 | Sun Pharmaceutical |
ICICI Securities Limited
|
1683.45 | 1895.00 |
1655.30 (1.70%) |
12.57 |
Buy
|
On a spree to expand specialty portfolio
ICICI Securities Limited
Sun Pharma (Sun) is acquiring US-based early-stage oncology-focused biotech company Checkpoint Therapeutics (Checkpoint) for an upfront cash payment of USD 4.1/share (total outgo of USD 355mn) and USD 0.7/share in cash in future milestones.
|
|||
10 Mar 2025 | Sun Pharmaceutical |
BOB Capital Markets Ltd.
|
1683.45 |
1611.50 (4.46%) |
|||||||
04 Feb 2025 | Sun Pharmaceutical |
KRChoksey
|
1683.45 | 1967.00 |
1765.25 (-4.63%) |
16.84 |
Accumulate
|
Specialty drugs and new product launches to drive growth
KRChoksey
Sun Pharma’s revenue was largely in-line with our estimates. However, EBITDA beat our estimates (+4.7%) due to lower-than-expected operating expenses and Adj. PAT beat our estimates due to better operating performance and better than expected other income.
|
|||
01 Feb 2025 | Sun Pharmaceutical |
BOB Capital Markets Ltd.
|
1683.45 | 2086.00 |
1742.20 (-3.37%) |
23.91 |
Buy
|
||||
21 Jan 2025 | Sun Pharmaceutical |
Emkay
|
1683.45 | 2400.00 |
1762.70 (-4.50%) |
42.56 |
Buy
|
Addressing the oral IL-23 antagonist challenge to Ilumya
Emkay
J&J, in a recent investor interaction, had stated that its oral IL-23 receptor antagonist peptide (Icotrokinra) could potentially compete with existing oral as well as injectable treatment options for moderate to severe plaque psoriasis.
|
|||
30 Oct 2024 | Sun Pharmaceutical |
KRChoksey
|
1683.45 | 1967.00 |
1852.10 (-9.11%) |
16.84 |
Accumulate
|
US Specialty and domestic business aid strong performance
KRChoksey
Sun Pharma revenue came in-line with our estimates (-1.0%) whereas EBITDA was largely in-line with our estimate (-2.1%) and Adj. PAT missed our estimate due to higher-than-expected finance costs and lower-than-expected other income.
|
|||
29 Oct 2024 | Sun Pharmaceutical |
ICICI Direct
|
1683.45 | 2185.00 |
1871.60 (-10.05%) |
29.79 |
Buy
|
||||
29 Oct 2024 | Sun Pharmaceutical |
BOB Capital Markets Ltd.
|
1683.45 | 2019.00 |
1871.60 (-10.05%) |
19.93 |
Hold
|
||||
28 Oct 2024 | Sun Pharmaceutical |
Sharekhan
|
1683.45 | 2264.00 |
1902.90 (-11.53%) |
34.49 |
Buy
|
Company surpasses expectations across multiple metrics
Sharekhan
Sun Pharmaceutical Industries reported a revenue of ?13,291 crore for the quarter, reflecting a 9% year-over-year increase and a 5% rise quarter-over-quarter. This figure surpassed our estimates by 2%, despite experiencing price reductions in Taro’s portfolio and in Japan.
|
|||
13 Aug 2024 | Sun Pharmaceutical |
KRChoksey
|
1683.45 | 1827.00 |
1740.10 (-3.26%) |
Target met |
Accumulate
|
Global Specialty and IPM growth to continue to drive growth
KRChoksey
SUNPHARMA exceeded our profitability estimates by a huge margin for Q1FY25. The EBITDA exceeded by 12% and EBITDA margins by 391 bps from our estimates while GPMs exceeded the expectations marginally by 36 bps from our estimates for Q1FY25.
|
|||
02 Aug 2024 | Sun Pharmaceutical |
ICICI Direct
|
1683.45 | 1845.00 |
1731.65 (-2.78%) |
Target met |
Hold
|
||||
01 Aug 2024 | Sun Pharmaceutical |
Motilal Oswal
|
1683.45 | 1980.00 |
1715.20 (-1.85%) |
17.62 |
Buy
|
||||
20 Jun 2024 | Sun Pharmaceutical |
Sharekhan
|
1683.45 | 1800.00 |
1471.00 (14.44%) |
Target met |
Buy
|
Dadra facility receiving WL to have no impact on the company’s financials
Sharekhan
Sun Pharma’s Dadra facility received a Warning Letter for a violation of cGMP regulations, which had previously received an Official Action Indicated (OAI) status on 11th Apr’24.
|
|||
10 Jun 2024 | Sun Pharmaceutical |
Geojit BNP Paribas
|
1683.45 | 1655.00 |
1513.10 (11.26%) |
Target met |
Hold
|
||||
23 May 2024 | Sun Pharmaceutical |
BOB Capital Markets Ltd.
|
1683.45 | 1530.00 |
1495.10 (12.60%) |
Target met |
Hold
|
||||
23 May 2024 | Sun Pharmaceutical |
ICICI Securities Limited
|
1683.45 | 1463.00 |
1495.10 (12.60%) |
Target met |
Hold
|
||||
23 May 2024 | Sun Pharmaceutical |
KRChoksey
|
1683.45 | 1827.00 |
1495.10 (12.60%) |
Target met |
Buy
|
Global Specialty and IPM growth to continue to drive growth
KRChoksey
Global specialty grew at 11.1% Y-o-Y (-8.7% Q-o-Q) to USD 271 Mn (19.1% of revenue) driven by ILLUMYA, Cequa, WINLEVI, and Odomzo in Q4FY24. It can be noted that large part of the global specialty sales accrue in the US.
|
|||
23 May 2024 | Sun Pharmaceutical |
ICICI Direct
|
1683.45 | 1530.00 |
1495.10 (12.60%) |
Target met |
Hold
|
||||
22 May 2024 | Sun Pharmaceutical |
Motilal Oswal
|
1683.45 | 1810.00 |
1539.30 (9.36%) |
Target met |
Buy
|
The US and India businesses drive earnings growth
Motilal Oswal
Sun Pharma (SUNP) reported a slight miss at the operational level for
4QFY24. This was due to lower-than-expected sales in the ROW market and higher-than-expected opex for the quarter. |
|||
23 Apr 2024 | Sun Pharmaceutical |
Motilal Oswal
|
1683.45 | 1870.00 |
1484.65 (13.39%) |
Target met |
Buy
|
||||
more
loading
|